Evidence map›Paper›PMID 32457752›Full record

ArticleFrontiers in immunology2020

Exacerbation of Nanoparticle-Induced Acute Pulmonary Inflammation in a Mouse Model of Metabolic Syndrome.

Saeed Alqahtani, Lisa M Kobos, Li Xia, Christina Ferreira, Jackeline Franco, Xuqin Du, Jonathan H Shannahan

Full text read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Oral Exposure To SiOCardiovascular toxicology · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Saeed AlqahtaniSchool of Health Sciences, College of Health and Human Sciences, Purdue University, West Lafayette, IN, United States.
Lisa M KobosSchool of Health Sciences, College of Health and Human Sciences, Purdue University, West Lafayette, IN, United States.
Li XiaSchool of Health Sciences, College of Health and Human Sciences, Purdue University, West Lafayette, IN, United States.
Christina FerreiraPurdue Metabolite Profiling Facility, Purdue University, West Lafayette, IN, United States.
Jackeline FrancoDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, United States.
Xuqin DuDepartment of Occupational Medicine and Toxicology, Beijing ChaoYang Hospital, Capital Medical University, Beijing, China.
Jonathan H ShannahanSchool of Health Sciences, College of Health and Human Sciences, Purdue University, West Lafayette, IN, United States.

Funding

Disease-Induced Modification in Nanoparticle-Corona Identity and ToxicityR00ES024392 · NIEHS · PURDUE UNIVERSITY · PI SHANNAHAN, JONATHAN HENRY · 2017 to 2019
$747k
NIEHS NIH HHS R00 ES024392
6 · The paper itself

Abstract

Nanotechnology has the capacity to revolutionize numerous fields and processes, however, exposure-induced health effects are of concern. The majority of nanoparticle (NP) safety evaluations have been performed utilizing healthy models and have demonstrated the potential for pulmonary toxicity. A growing proportion of individuals suffer diseases that may enhance their susceptibility to exposures. Specifically, metabolic syndrome (MetS) is increasingly prevalent and is a risk factor for the development of chronic diseases including type-2 diabetes, cardiovascular disease, and cancer. MetS is a combination of conditions which includes dyslipidemia, obesity, hypertension, and insulin resistance. Due to the role of lipids in inflammatory signaling, we hypothesize that MetS-associated dyslipidemia may modulate NP-induced immune responses. To examine this hypothesis, mice were fed either a control diet or a high-fat western diet (HFWD) for 14-weeks. A subset of mice were treated with atorvastatin for the final 7-weeks to modulate lipids. Mice were exposed to silver NPs (AgNPs) via oropharyngeal aspiration and acute toxicity endpoints were evaluated 24-h post-exposure. Mice on the HFWD demonstrated MetS-associated alterations such as increased body weight and cholesterol compared to control-diet mice. Cytometry analysis of bronchoalveolar lavage fluid (BALF) demonstrated exacerbation of AgNP-induced neutrophilic influx in MetS mice compared to healthy. Additionally, enhanced proinflammatory mRNA expression and protein levels of monocyte chemoattractant protein-1, macrophage inflammatory protein-2, and interleukin-6 were observed in MetS mice compared to healthy following exposure. AgNP exposure reduced mRNA expression of enzymes involved in lipid metabolism, such as arachidonate 5-lipoxygenase and arachidonate 15-lipoxygenase in both mouse models. Exposure to AgNPs decreased inducible nitric oxide synthase gene expression in MetS mice. An exploratory lipidomic profiling approach was utilized to screen lipid mediators involved in pulmonary inflammation. This assessment indicates the potential for reduced levels of lipids mediators of inflammatory resolution (LMIR) in the MetS model compared to healthy mice following AgNP exposure. Statin treatment inhibited enhanced inflammatory responses as well as alterations in LMIR observed in the MetS model due to AgNP exposure. Taken together our data suggests that MetS exacerbates the acute toxicity induced by AgNPs exposure possibly via a disruption of LMIR leading to enhanced pulmonary inflammation.

Indexed as

SilverAnimalsAtorvastatinDiet, High-FatDiet, WesternDisease Models, AnimalDisease SusceptibilityHydroxymethylglutaryl-CoA Reductase InhibitorsLipid MetabolismMaleMetabolic SyndromeMetal NanoparticlesMiceMice, Inbred C57BLPneumoniaReal-Time Polymerase Chain ReactionAtorvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsRNA, MessengerSilveracute inflammationlipid mediators of inflammatory resolutionnanotoxicologysilver nanoparticlesstatinsusceptibility

Identifiers

PMID32457752
PMCPMC7221136

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.